Stocktoria
X4 Pharmaceuticals, Inc XFOR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-11-16
X4 Pharmaceuticals, Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -247.4% | -1400.0% | — | — | — |
| Net margin | -225.6% | -1440.4% | — | — | — |
| FCF margin | — | -5047.2% | — | — | — |
| Return on assets | -27.3% | -25.6% | -68.7% | -60.3% | -75.7% |
| Return on equity | -42.5% | -169.1% | -198.0% | -126.8% | -137.7% |
| Debt / equity | 0.40× | 3.39× | 1.08× | 0.44× | 0.51× |
| Current ratio | 10.16 | 3.41 | 5.34 | 5.76 | 6.27 |
| Revenue growth | 1250.5% | — | — | — | -100.0% |
Source: SEC EDGAR filings · CIK 0001501697 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.